Overcoming NTDs
Introduction of Global Public-Private Partnership Initiatives
Horizontal scrolling is available
| Participation in the London Declaration against Neglected Tropical Diseases | In January 2012, Eisai, along with 12 other global pharmaceutical companies, the Bill & Melinda Gates Foundation, the World Health Organization (WHO), the World Bank, the governments of the United States and the United Kingdom, and governments of NTD-endemic countries, formed the largest international public-private partnership in global health to work together to eliminate 10 NTDs by 2020. The London Declaration, a joint statement of commitment to work together to eliminate 10 NTDs by 2020. |
|---|---|
| Signing the Kigali Declaration, a public-private partnership for the control of neglected tropical diseases | In June 2022, Eisai signed the Kigali Declaration, which was presented at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) held in Kigali, the capital of the Republic of Rwanda. The Declaration, the successor to the London Declaration, aims to eradicate two NTDs by 2030, eliminate at least one NTD in 100 countries, and reduce the number of people who need to take action against NTDs by 90% through cross-sector partnerships.
Please also watch the video summarizing the pharmaceutical industry's joint fight against NTDs.
 |
Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership originating in Japan
In 2013, Japan launched the Global Health Innovative Technology Fund (GHITF), a groundbreaking public-private partnership in which the private sector takes the initiative and participates as a funding partner. The GHIT Fund is the world's first public-private partnership of government, business, and citizens working across sectoral boundaries to jointly fund global health R&D. The Fund is a non-profit, non-profit, non-profit organization dedicated to the advancement of global health R&D. The Fund is a non-profit, non-profit, non-profit organization dedicated to the advancement of global health R&D. The Fund is the first of its kind in the world to be established in Japan. The GHIT Fund is the world's first fund dedicated to global health research and development. It provides grants for joint Japanese and international R&D projects on the three major infectious diseases and neglected tropical diseases to research, develop, and commercialize medicines, vaccines, and diagnostics needed by the poorest people in developing countries.
GHIT Participating Companies
The companies participating as partners in the GHIT Fund are as follows (as of April 2024)
| Full Partner | Astellas Pharma Inc., Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Shionogi, Takeda Pharmaceutical Company Limited |
|---|---|
| Associate Partner | Fujirebio, Otsuka Pharmaceutical, Remedy & Company, Inc. |
| Affiliate Partners | FUJIFILM Corporation, Kyowa Kirin Company, Limited, Merck K.K., Mitsubishi Tanabe Pharma Corporation, Sumitomo Pharma Corporation |
JAPIA aims to strengthen Japan's international contribution in the field of global health through the creation of new drugs for infectious diseases in developing countries by leveraging our strengths in new drug development based on our advanced science and technology.